- Home
- IHT vs TPST Comparison
IHT vs TPST Comparison
Compare IHT & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IHT | TPST |
|---|---|---|
| Founded | 1971 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2M | 15.6M |
| IPO Year | 1995 | 2012 |
Fundamental Metrics
Financial Performance| Metric | IHT | TPST |
|---|---|---|
| Price | $1.30 | $1.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 18.2K | ★ 227.6K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.77% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $7,600,000.00 | $295,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.33 | N/A |
| 52 Week Low | $0.95 | $0.84 |
| 52 Week High | $4.24 | $12.22 |
Technical Indicators
Market Signals| Indicator | IHT | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 29.68 | 54.36 |
| Support Level | $1.26 | $1.02 |
| Resistance Level | $1.51 | $1.26 |
| Average True Range (ATR) | 0.13 | 0.09 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 13.27 | 39.80 |
Price Performance
Historical ComparisonAbout IHT InnSuites Hospitality Trust Shares of Beneficial Interest
InnSuites Hospitality Trust is a real estate investment trust. It is engaged in the ownership and operation of hotel properties. It owns interests in two hotels, operates and provides management services, and provides trademark license services, for two hotels. The Trust also holds an investment related to clean energy electricity generation technology and manages an option to acquire an investment in an independent boutique hotel reservation and hotel services business.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.